Cost-effectiveness analysis of memantine for moderate-to-severe Alzheimer's disease in the Netherlands

Bart Hoogveldt1, Benoît Rive2, Johan Severens3, Khaled Maman4, Chantal Guilhaume51Field Product Management, Lundbeck BV, Amsterdam, The Netherlands; 2Global Outcomes Research, Lundbeck SAS, Issy-les-Moulineaux, France; 3Institute of Health Policy and Management, Erasmus University Rotterdam, The Netherlands; 4Creativ Research SAS, Paris, France; 5Global Evidence and Value Development, Sanofi-Aventis, Paris, FranceObjective: The purpose of this study was to estimate the cost-effectiveness of memantine relative to standard care in patients with moderate-to-severe Alzheimer's disease in the Nethe... Mehr ...